Loading company
Tvardi Therapeutics, Inc.
TVRD · Nasdaq · ·
$1.29-2.6%Sep 29 close
- 1M
- -29.1%
- 6M
- -59.7%
- 1Y
- -96.7%
- 5Y
- -99.8%
TVRD · Nasdaq · ·
$1.29-2.6%Sep 29 close
The quarter ending March 31, 2025, against the same quarter a year earlier.
| Measure | 3 months toMar 31, 2025 | 3 months toMar 31, 2024 | Change |
|---|---|---|---|
| Total Revenue | $2.6M | $2.1M | +20.33% |
| Profit | -$6.5M | $4.2M | -254.96% |
| Profit per share | -$0.69 | $0.49 | -240.02% |
| Free Cash Flow | -$4.8M | -$19.4M | +75.12% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Tvardi Therapeutics, Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases with significant unmet need. STAT3 is a central mediator across critical signaling pathways that drive uncontrolled proliferation, survival and immune dysregulation. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The Company is conducting clinical trials with TTI-109 in healthy volunteers and TTI-101 in hepatocellular carcinoma ( NCT05440708 ). To learn more, please visit tvarditherapeutics.com or follow us on LinkedIn and X (Twitter) .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Tvardi Therapeutics, Inc.’s Item 2.02 8-K filed August 14, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.